TIG - TiGenix NV

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
47.59
+0.03 (+0.06%)
At close: 9:30AM EDT
Stock chart is not supported by your current browser
Previous Close47.56
Open45.46
Bid41.61 x 800
Ask48.99 x 300
Day's Range47.59 - 47.59
52 Week Range19.24 - 48.00
Volume5
Avg. Volume1,758
Market Cap746.797M
Beta-0.03
PE Ratio (TTM)N/A
EPS (TTM)-6.60
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.47
Trade prices are not sourced from all markets
  • GlobeNewswire13 days ago

    Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid

    The number of Securities tendered into the Bid, together with all Securities owned by Takeda and its affiliates, represents or gives access to 96.03% of the voting rights represented or given access to by all of the outstanding Securities on a fully diluted basis. Following settlement of the Securities, Takeda will own 96.08% of the outstanding Ordinary Shares (including Ordinary Shares represented by ADSs) and will have acquired 95.76% of the Ordinary Shares that were the subject of the Bid.

  • Business Wire13 days ago

    Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid in respect of TiGenix and Commencement of Simplified Squeeze-out and Intention to Delist the ADSs from Nasdaq...

    The number of Securities tendered into the Bid, together with all Securities owned by Takeda and its affiliates, represents or gives access to 96.03% of the voting rights represented or given access to by all of the outstanding Securities on a fully diluted basis. Following settlement of the Securities, Takeda will own 96.08% of the outstanding Ordinary Shares (including Ordinary Shares represented by ADSs) and will have acquired 95.76% of the Ordinary Shares that were the subject of the Bid. Following the squeeze-out, TiGenix will become a wholly owned subsidiary of Takeda and the Ordinary Shares will be automatically delisted from Euronext Brussels.

  • GlobeNewswire16 days ago

    TiGenix: Transparency Information

    Leuven- July 2, 2018, 22:00 h CET- TiGenix NV publishes information in accordance with articles 15 and 18 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose ...

  • GlobeNewswire21 days ago

    TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007

    Transparency notification pursuant to Article 14 of the Law of May 2, 2007. Leuven- June 27, 2018, 22:00 h CET- TiGenix NV announced today that it received a transparency notification pursuant to Article ...

  • GlobeNewswire26 days ago

    TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007

    Transparency notification pursuant to Article 14 of the Law of May 2, 2007. Leuven- June 22, 2018, 22:00 h CET- TiGenix NV announced today that it received a transparency notification pursuant to Article ...

  • GlobeNewswire29 days ago

    TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007

    Transparency notifications pursuant to Article 14 of the Law of May 2, 2007. Leuven- June 19, 2018, 22:00 h CET- TiGenix NV announced today that it received transparency notifications pursuant to Article ...

  • GlobeNewswirelast month

    Transparency notification pursuant to Article 14 of the Law of May 2, 2007

    Transparency notification pursuant to Article 14 of the Law of May 2, 2007. Leuven- June 14, 2018, 22:00 h CET- TiGenix NV announced today that it received a transparency notification pursuant to Article ...

  • GlobeNewswirelast month

    TiGenix announces a change in its Board of Directors and its Management Team

    June 13, 2018, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, today announces that Eduardo Bravo will depart the board of directors and his role as CEO of TiGenix effective as of June 15, 2018. Following the successful result of the first acceptance period of the takeover bid by Takeda, Eduardo Bravo will be succeeded as a member of the board of directors by Sebastian Wehle. Sebastian will also be in charge of the daily management of TiGenix together with Claudia D'Augusta, CFO of TiGenix, who was granted powers of daily management with a view to ensuring the smooth integration of TiGenix's operations into Takeda, to the extent legally permitted.

  • GlobeNewswirelast month

    Takeda and TiGenix Announce Results of First Acceptance Period for the Voluntary and Conditional Public Takeover Bid of TiGenix and Commencement of Second Acceptance Period

    The number of Securities tendered into the Bid, together with all Securities owned by Takeda and its affiliates, represents or gives access to 90.83% of the voting rights represented or given access to by all of the outstanding Securities on a fully diluted basis. Takeda announces that the conditions of the Bid have been satisfied. Takeda will accept for payment all Securities validly tendered and not withdrawn during the first acceptance period.

  • Business Wirelast month

    Takeda and TiGenix Announce Results of First Acceptance Period for the Voluntary and Conditional Public Takeover Bid of TiGenix and Commencement of Second Acceptance Period

    Takeda Pharmaceutical Company Limited (4502.T) (“Takeda”) and TiGenix NV (Euronext Brussels and Nasdaq: TIG) (“TiGenix”) today announced the results of the first acceptance period of Takeda’s previously announced tender offer (the “Bid”) in cash for all outstanding ordinary shares (“Ordinary Shares”), warrants (“Warrants”) and American Depositary Shares (“ADSs,” and together with the Ordinary Shares and the Warrants, the “Securities”) of TiGenix that are not yet owned by Takeda and its affiliates, which expired as scheduled on May 31, 2018, at 4 p.m. CEST/10 a.m. EDT.

  • Insider Q&A: How to invest in 'opportunity zones'
    Associated Presslast month

    Insider Q&A: How to invest in 'opportunity zones'

    The brand new "opportunity zones" enable private investors to re-invest their profits into businesses that are located in parts of the country that are generally starved from outside investment. John Lettieri, co-founder and president of the Economic Innovation Group in Washington, DC, helped to design this new tax incentive and explained how it will likely work. Q: What is an opportunity zone?

  • GlobeNewswire2 months ago

    TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007

    Transparency notifications pursuant to Article 14 of the Law of May 2, 2007. Leuven- May 28, 2018, 22:00 h CET- TiGenix NV announced today that it received transparency notifications pursuant to Article ...

  • Business Wire2 months ago

    Takeda Announces Information Related to its Pending Voluntary and Conditional Public Takeover Bid for Outstanding Shares and American Depositary Shares of TiGenix

    Takeda Pharmaceutical Company Limited today announced information related to its previously announced and ongoing tender offer in cash for all outstanding ordinary shares , warrants and American Depositary Shares of TiGenix NV that are not yet owned by Takeda and its affiliates, in two separate, but concurrent and related offers in Belgium and in the United States (the “U.S.

  • GlobeNewswire2 months ago

    TiGenix:Transparency notifications pursuant to Article 14 of the Law of May 2, 2007

    Transparency notifications pursuant to Article 14 of the Law of May 2, 2007. Leuven- May 14, 2018, 22:00 h CET- TiGenix NV announced today that it received transparency notifications pursuant to Article ...

  • TiGenix NV (EBR:TIG): Immense Growth Potential?
    Simply Wall St.2 months ago

    TiGenix NV (EBR:TIG): Immense Growth Potential?

    The latest earnings announcement TiGenix NV’s (ENXTBR:TIG) released in December 2017 revealed that the business entered the red zone with earnings dropping into the negative territory as a result ofRead More...

  • GlobeNewswire2 months ago

    TiGenix: CONVENING NOTICE TO THE ANNUAL SHAREHOLDERS' MEETING TO BE HELD ON 7 JUNE 2018

    The board of directors of TiGenix NV (the "Company") is pleased to invite you to the annual shareholders' meeting of TiGenix NV that will be held on 7 June 2018 at 14:00h at the Faculty Club, Groot Begijnhof 14, 3000 Leuven, with the agenda and proposed resolutions set out below.

  • GlobeNewswire3 months ago

    TiGenix: Publication of prospectus and response memorandum for Takeda takeover bid commencing on April 30, 2018

    April 27, 2018, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG) ("TiGenix"), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, today announces the publication of the prospectus and response memorandum in relation to the previously announced voluntary and conditional public takeover bid by Takeda Pharmaceutical Company Limited ("Takeda") to acquire TiGenix (the "Bid"). The Bid relates to all outstanding ordinary shares ("Ordinary Shares"), warrants ("Warrants") and American Depositary Shares ("ADSs" and together with the Ordinary Shares and the Warrants, the "Securities") of TiGenix that are not yet owned by Takeda and its affiliates and will be comprised of two separate offers: (i) an offer to all holders of Ordinary Shares and Warrants in accordance with the applicable law in Belgium (the "Belgian Offer"), and (ii) an offer to holders of ADSs, wherever located, and to holders of Ordinary Shares who are resident in the U.S. in accordance with applicable U.S. law (the "U.S. Offer").

  • GlobeNewswire3 months ago

    TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007

    Transparency notifications pursuant to Article 14 of the Law of May 2, 2007. Leuven- April 26, 2018, 22:00 h CET- TiGenix NV announced today that it received transparency notifications pursuant to Article ...

  • Why Tech Invest Group SA.’s (WSE:TIG) Ownership Structure Is Important
    Simply Wall St.3 months ago

    Why Tech Invest Group SA.’s (WSE:TIG) Ownership Structure Is Important

    I am going to take a deep dive into Tech Invest Group SA.’s (WSE:TIG) most recent ownership structure, not a frequent subject of discussion among individual investors. A company’s ownershipRead More...

  • Why TiGenix NV’s (EBR:TIG) Ownership Structure Is Important
    Simply Wall St.4 months ago

    Why TiGenix NV’s (EBR:TIG) Ownership Structure Is Important

    In this analysis, my focus will be on developing a perspective on TiGenix NV’s (ENXTBR:TIG) latest ownership structure, a less discussed, but important factor. A company’s ownership structure is oftenRead More...

  • PR Newswire4 months ago

    TiGenix and Takeda Announce Alofisel® (darvadstrocel) Receives Approval to Treat Complex Perianal Fistulas in Crohn's Disease in Europe

    TiGenix NV (Euronext Brussels and NASDAQ: TIG) ("TiGenix") and Takeda Pharmaceutical Company Limited (4502.T) ("Takeda") today announced that the European Commission (EC) has approved Alofisel (darvadstrocel), previously Cx601, for the treatment of complex perianal fistulas in adult patients with nonactive/mildly active luminal Crohn's disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. Alofisel should be used after conditioning of fistula.[2] This marks the first allogeneic stem cell therapy to receive central marketing authorization (MA) approval in Europe.